Topical delivery of therapeutic agents using cell-permeable peptides for the treatment of age-related macular degeneration and other eye diseases

摘要

The present disclosure provides therapeutic agents for the treatment of age-related macular degeneration (AMD) and other eye diseases. AMD at any stage (including early, middle and advanced stages), and any phenotype of AMD (geographic atrophy (eg, non-central GA or central GA) and neovascularization, using one or more therapeutic agents. Blood vessels (including, eg, type 1, 2 or 3 NV) can be treated. In some embodiments, the therapeutic agent may be an antidyslipidemia agent, an antioxidant, an anti-inflammatory agent, a complement inhibitor, a neuroprotective agent or an anti-angiogenic agent, or any combination thereof. Is or includes. In certain embodiments, the therapeutic agent is, or comprises, an anti-dyslipidemia agent (eg, an apolipoprotein mimetic and / and a statin). In some embodiments, the therapeutic agent is mixed, non-covalently or covalently linked to a cell-permeable peptide (CPP) or encapsulated in CPP-modified nanoparticles, micelles or liposomes. Or modified (eg, lumped, prenylated, lipid-added, or linked to a small molecule α-helix mimic) to acquire membrane translocation ability. In certain embodiments, the one or more therapeutic agents are administered by eye drops. [Selection diagram] Fig. 1